乳腺癌病史与甲状腺癌特异性死亡率降低之间的关联
该比较队列研究基于监测、流行病学和最终结果(SEER)18数据库,纳入5598例甲状腺乳头状癌(PTC)和604例甲状腺滤泡状癌(FTC)且有乳腺癌(BC)病史的患者,并与倾向评分匹配的无BC病史甲状腺癌患者比较。结果显示,有BC病史的PTC和FTC患者甲状腺癌特异性死亡率均更低,PTC风险比(HR)为0.472(95%CI 0.370-0.601),FTC为0.656(95%CI 0.461-0.934)。作者认为BC病史对甲状腺癌特异性生存具有保护作用。
要点
- 有BC病史的PTC患者甲状腺癌特异性死亡率为1.3%,匹配无BC病史者为2.6%,HR 0.472(95%CI 0.370-0.601)。
- 有BC病史的FTC患者甲状腺癌特异性死亡率为5.8%,匹配无BC病史者为8.4%,HR 0.656(95%CI 0.461-0.934)。
- PTC中甲状腺癌先于BC发生时HR为0.397(95%CI 0.268-0.588),BC先于甲状腺癌发生时HR为0.607(95%CI 0.445-0.827)。
核心结论
- 本研究显示乳腺癌病史对甲状腺癌特异性患者生存具有稳健的保护效应,这对该类患者更精确的预后判断有重要意义。
研究设计与样本
- 比较队列研究,基于监测、流行病学和最终结果(SEER)18数据库,纳入5598例甲状腺乳头状癌(PTC)和604例甲状腺滤泡状癌(FTC)且有乳腺癌(BC)病史的患者,并与倾向评分匹配的无BC病史甲状腺癌患者比较。
- 主要结局指标为甲状腺癌特异性死亡率。
主要发现
- 有BC病史的PTC患者甲状腺癌远处转移率为2.4%,匹配无BC病史者为3.0%;FTC分别为6.1% vs 9.1%(均P < .05)。
- 有BC病史的PTC患者甲状腺癌特异性死亡率为1.3%,匹配无BC病史者为2.6%;FTC分别为5.8% vs 8.4%(均P < .05)。
- 有BC病史与匹配无BC病史患者比较,PTC死亡HR为0.472(95%CI 0.370-0.601),FTC为0.656(95%CI 0.461-0.934)(均P < .05)。
- PTC中甲状腺癌先于BC发生时死亡HR为0.397(95%CI 0.268-0.588;P < .001),BC先于甲状腺癌发生时HR为0.607(95%CI 0.445-0.827;P = .002)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: The clinical relevance of the well-known association between thyroid cancer (TC) and breast cancer (BC) remains to be further defined. OBJECTIVE: This work aimed to investigate the effect of history of BC on the prognosis of TC. METHODS: This was a comparative cohort study of tumor behaviors and TC-specific mortality in 5598 patients with papillary thyroid cancer (PTC) and 604 patients with follicular thyroid cancer (FTC), all with a history of BC (TC-BC patients), and their propensity score-matched TC patients without a history of BC (TCnoBC patients) in Surveillance, Epidemiology and End Results (SEER) 18. The main outcome measure was TC-specific mortality. RESULTS: Lower TC distant metastasis rates of 2.4% vs 3.0% in PTC and 6.1% vs 9.1% in FTC and TC-specific mortality rates of 1.3% vs 2.6% in PTC and 5.8% vs 8.4% in FTC were found in TC-BC patients vs matched TCnoBC patients (all P < .05). Comparing TC-BC patients with matched TCnoBC patients, hazard ratios (HRs) for mortality were 0.472 (95% CI, 0.370-0.601) in PTC and 0.656 (95% CI, 0.461-0.934) in FTC (all P < .05). Such HRs for mortality in PTC were 0.397 (95% CI, 0.268-0.588; P < .001) when TC occurred before BC vs 0.607 (95% CI, 0.445-0.827; P = .002) when BC occurred before TC. CONCLUSION: This study demonstrates a robust protective effect of a history of BC on TC-specific patient survival, which has strong implications for more precise prognostication of TC in such patients.
引用
- Lin S, Wang Z, Xing M, et al. Association Between a History of Breast Cancer and Decreased Thyroid Cancer-specific Mortality. J Clin Endocrinol Metab. 2024. PMID: 38064679. doi:10.1210/clinem/dgad722
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。